The World Economic Forum proposes creating a pairing mechanism for vaccine innovators and vaccine manufacturers. It aims to protect both innovators, who will find capacity to produce, and manufacturers, who will access vaccine candidates at the right clinical development pathways – i.e. when they reach phase 3 and no earlier, hence averting the need for innovators to unilaterally and exclusively secure large capacities from individual manufacturers while their vaccines are yet unproven.
The Developing Countries Vaccine Manufacturers Network (DCVMN) accounts for the majority of vaccines produced at more than 65% in each WHO region except the European Region (EUR). This network of 40 manufacturers, located in developing countries such as India, Indonesia, South Korea, Brazil, China, South Africa, needs to be put to work.
A mechanism like the one described in the above would represent a departure from the way traditional market forces are traditionally shaping the vaccine manufacturing landscape, by encouraging bilateral agreements between vaccine researchers and manufacturers.
The current supply, even if the world were suddenly to switch en masse from manufacturing existing vaccines to manufacturing one for COVID-19, is not commensurate with the need to vaccinate populations in their billions in order to end the present crisis.
*Arnaud Bernaert, Head of Health, World Economic Forum